HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reaffirmed a Buy rating on Acurx Pharmaceuticals (NASDAQ:ACXP) and increased the price target from $13 to $14, indicating a positive outlook on the company's stock.
December 15, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Acurx Pharmaceuticals and raises the price target from $13 to $14, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, which can lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100